Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015, 159(2):192-196 | DOI: 10.5507/bp.2014.061

The role of tissue factor in normal pregnancy and in the development of preeclampsia: A review

Jana Prochazkovaa, Ludek Slavika, Jana Ulehlovaa, Martin Prochazkab,c
a Department of Hemato-oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
b Department of Obstetrics and Gynecology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc
c Department of Midwifery, Faculty of Health Sciences, Palacky University Olomouc

Background: Tissue factor (TF) is a key element for normal gestation, especially in the first trimester. TF levels are hence raised in pregnancy, producing an adaptive hypercoagulable state. Potentiated hypercoagulability however, is associated with disorders of pregnancy such as pre-eclampsia but the results of TF and its inhibitor, tissue factor pathway inhibitor (TFPI), measurement, in pre eclampsic women are ambiguous and the data conflicting. This review covers the current knowledge status of the role of TF assessment in pregnancy with a focus on its diagnostic utility.

Methods: A review of the literature using the following key words: tissue factor, thrombosis, inflammation, pregnancy, preeclampsia.

Results: The published literature shows raised and unchanged TF levels in various studies of pre-eclampsia along with equally conflicting data for TFPI. The various study designs and methods used in these studies makes valid comparison difficult. Meta analysis of 34 randomized trials showed that low-dose aspirin in early phases of gravidity (starting from the 16th week or earlier) significantly reduces the incidence of preeclampsia.

Conclusions: Overall, the results of the literature search together with knowledge of the structure and biological effects of TF, suggest that measuring the level of plasma TF/TFPI is not ideal for determining the actual levels of TF in the uteroplacental circulation. The current view that endothelial dysfunction is the trigger for preeclampsia, suggests that aspirin may be an effective prophylaxis. Further research will be necessary: measuring the expression of tissue factor on monocytes using flowcytometry and comparing the development of this expression during normal pregnancy and pregnancy complicated by preeclampsia, for example. Another possibility is immunohistochemical determination of the level of TF expression directly in placental tissue.

Keywords: tissue factor, thrombosis, inflammation, pregnancy, preeclampsia

Received: May 3, 2014; Accepted: November 13, 2014; Prepublished online: December 22, 2014; Published: June 28, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prochazkova, J., Slavik, L., Ulehlova, J., & Prochazka, M. (2015). The role of tissue factor in normal pregnancy and in the development of preeclampsia: A review. Biomedical papers, 159(2), 192-196. doi: 10.5507/bp.2014.061
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chu AJ. Tissue Factor, Blood Coagulation, and Beyond: An Overview. International Journal of Inflammation 2011;Article ID 367284, 30 pages, doi:10.4061/2011/367284 Go to original source... Go to PubMed...
    2. Petersen LC, Valentin S, Hedner U. Regulation of the extrinsic pathway systém in health and disease: the role of factor VII a and tissue factor pathway inhibitor. Thrombosis Research 1995;79(1):1-47. Go to original source... Go to PubMed...
    3. Chu AJ. Tissue factor mediates inflammation. Archives of Biochemistry and Biophysics 2005;440(2):123-32. Go to original source... Go to PubMed...
    4. Kittur FS, Manithody C, Morrisey JH, Rezaie AR. The cofactor function of the N-terminal domain of tissue factor. Journal of Biological Chemistry 2004;279(38):39745-9. Go to original source... Go to PubMed...
    5. Østerud B, Bjørklid E. Sources of tissue factor. Seminars in Thrombosis and Hemostasis 2006;32(1):11-23. Go to original source... Go to PubMed...
    6. Drake TA, Morrisey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989;134:1087-97.
    7. Flössel C, Luther T, Müller M, Albrecht S, Kasper M. Immunohistochemical detection of tissue factor (TF) in paraffin sections of routinely fixed human tissue. Histochemistry 1994;101:448-53. Go to original source... Go to PubMed...
    8. Key NS, Mackman N. Tissue factor and its measurement in whole blood, plasma and microparticles. Seminars in Thrombosis and Hemostasis 2010;36(8):865-75. Go to original source... Go to PubMed...
    9. Muller I, Klocke A, Alex M, Kotzch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, Engelmann B. Intravascular tissue factor iniciates coagulation via circulating microvesicles and plateles. FASEB Journal 2003;17:476-8. Go to original source... Go to PubMed...
    10. Berckmans RJ, Neiuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001;85:639-46. Go to original source... Go to PubMed...
    11. Albrecht S, Kotzch M, Siegert G, Luther T, Grossmann H, Grosser M, Müller M. Detection of circulating tissue factor aand factor VII in a normal population. Thromb Haemost 1996;75:772-7. Go to original source... Go to PubMed...
    12. Carlsson K, Freskgard, PO, Persson E, Carlsson U, Svensson M. Probing the interface between factor Xa and tissue factor in the quaternary complex tissue factor-factor VIIa-factor Xa-tissue factor pathway inhibitor. Eur J Biochem 2003;270(12):2576-82. Go to original source... Go to PubMed...
    13. Mackman N. Role of Tissue Factor in Haemostasis, Thrombosis, and Vascular Development. Arterioscler Thromb Vasc Biol 2004; 24:1015-22. Go to original source... Go to PubMed...
    14. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arteiroscler Thromb Vasc Biol 2005;25:1545-50. Go to original source... Go to PubMed...
    15. Rosen ED, Chan JCY, Idusogie E, Clotman F, Vlasuk G, Luther T, Jalbert LR, Albrecht S, Zhong L, Lissens A, Schoonjans L, Moons L, Collen D, Castellino FJ, Carmeliet P. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 1997;390:290-4. Go to original source... Go to PubMed...
    16. Sandset PM. Tissue factor pathway inhibitor (TFPI) - an update. Haemostasis 1996;26:154-65. Go to original source... Go to PubMed...
    17. Broze Jr GJ. Tissue factor pathway inhibitor. Thromb Haemost 1995;74:90-3. Go to original source... Go to PubMed...
    18. Osterud B, Bajaj MS, Bajaj SP. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiological and pathological conditions. Thromb Haemost 1995;73:873-5. Go to original source... Go to PubMed...
    19. Van Hinsbergh VWM: Endothelium - role in regulation of coagulation and inflammation. Semin Imunopathol 2012;34(1):93-106. Go to original source... Go to PubMed...
    20. Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB. Identification of active tissue factor in human coronary atheroma. Circulation 1996;94:1226-32. Go to original source... Go to PubMed...
    21. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur JD, Nemerson Y. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997;78:200-4. Go to original source... Go to PubMed...
    22. Bouma BN, Meijers JC. New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R). Seminars in Hematology 2004;41(1),S1:13-9. Go to original source...
    23. Guimarães AHC, Rijken DC. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model. Journal of Thrombosis and Haemostasis 2004;91(3):473-9. Go to original source... Go to PubMed...
    24. Mandl-Weber S, Haslinger B, Sitter T. Thrombin upregulates production of plasminogen activator inhibitor type 1 in human peritoneal mesothelial cells. Peritoneal Dialysis International 1999;19(4):319-24. Go to original source... Go to PubMed...
    25. Chambers RC, Laurent GJ. Coagulation cascade proteases and tissue fibrosis. Biochemical Society Transactions 2002;30(2):194-200. Go to original source... Go to PubMed...
    26. Ramachandran R, Hollenberg MD. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. British Journal of Pharmacology 2008;153(1):S263-82. Go to original source... Go to PubMed...
    27. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proceedings of the National Academy of Sciences of the United States of America 2001;98(14):7742-7. Go to original source... Go to PubMed...
    28. White B, Perry D. Acquired antithrombin deficiency in sepsis. British Journal of Haematology 2001;112(1):26-31. Go to original source... Go to PubMed...
    29. Asakura H, Ontachi Y, Mizutani T, Kato M, Ito T, Saito M, Morishita E, Yamazaki M, Aoshima K, Takami A, Yoshida T, Suga Y, Miyamoto K, Nakao S. Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. European Journal of Haematology 2001;67(3):170-5. Go to original source... Go to PubMed...
    30. Camerer E, Røttingen J-A, Gjernes E, Larsen K, Skartlien AH, Iversen JG, Prydz H. Coagulation factors VIIa and Xa induce cell signaling leading to up- regulation of the egr-1 gene. Journal of Biological Chemistry 1999;274(45):32225-33. Go to original source... Go to PubMed...
    31. Chen D, Riesbeck K, McVey JH, Kemball-Cook G, Tuddenham EG, Lechler RI, Dorling A. Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins. Xenotransplantation 2001;8(4):258-65. Go to original source... Go to PubMed...
    32. Lindmark E, Siegbahn A. Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin. Thrombosis Research 2002;108(1):77-84. Go to original source... Go to PubMed...
    33. Pernerstorfer T, Hollenstein U, Hansen JB, Knechtelsdorfer M, Stohlawetz P, Graninger W, Eichler HG, Speiser W, Jilma B. Heparin blunts endotoxin-induced coagulation activation. Circulation 1999;100(25):2485-90. Go to original source... Go to PubMed...
    34. Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D, Fedi S, Giusti B, Brunelli T, Giusti B, Brunelli T, Comeglio P, Gensini GF, Neri Serneri GG. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Journal of Thrombosis and Haemostasis 1999;81(4):589-93. Go to original source... Go to PubMed...
    35. Gertz SD, Fallon JT, Gallo R, Taubman MB, Banai S, Barry WL, Gimple LW, Nemerson Y, Thiruvikraman S, Naidu SS, Chesebro JH, Fuster V, Sarembock IJ, Badimon JJ. Hirudin reduces tissue factor expression in neointima after ballon injury in rabbit femoral and porcine coronary arteries. Circulation 1998;98:580-7. Go to original source... Go to PubMed...
    36. Hölschermann H, Bohle RM, Schmidt H, Zeller H, Fink L, Stahl U, Grimm H, Tillmanns H, Haberbosch W. Hirudin reduces tissue factor expression and attenuates graft arteriosclerosis in rat cardiac allografts. Circulation 2000;102(3):357-63. Go to original source... Go to PubMed...
    37. Souter PJ, Thomas S, Hubbard AR, Poole S, Römisch J, Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Critical Care Medicine 2001;29(1):134-9. Go to original source... Go to PubMed...
    38. Arai M, Uchiba M, Komura H, Mizuochi Y, Harada N, Okajima K. Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. Journal of Pharmacology and Experimental Therapeutics 2010;334(1):206-13. Go to original source... Go to PubMed...
    39. Napoleone E, Di Santo A, Camera M, Tremoli E, Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circulation Research 2000;86(2):139-43. Go to original source... Go to PubMed...
    40. Steffel J, Hermann M, Greutert H, Gay S, Lüscher TF, Ruschitzka F, Tanner FC. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 2005;111(13):1685-89. Go to original source... Go to PubMed...
    41. Kunieda Y, Nakagawa K, Nishimura H, Kato H, Ukimura N, Yano S, Kawano H, Kimura S, Nakagawa M, Tsuji H. HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Thrombosis Research 2003;110(4):227-34. Go to original source... Go to PubMed...
    42. Wang HY, Yang YM, Zhuang Y, Chen HN, Wan YL, Huang YT. The effect of celecoxib on tissue factor expression in pancreatic cancer cells. Chinese Medical Journal 2007;120(20):1753-6. Go to original source...
    43. Wei JL, Cui HM, Ma CY. Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. European Journal of Medical Research 2007;12(5):216-21. Go to PubMed...
    44. Hölschermann H, Terhalle HM, Zakel U, Maus U, Parviz B, Tillmanns H, Haberbosch W. Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives. Journal of Thrombosis and Haemostasis 1999;82(6):1614-20. Go to original source... Go to PubMed...
    45. Reddy KV, Bhattacharjee G, Schabbauer G, Hollis A, Kempf K, Tencati M, O'Connell M, Guha M, Mackman N. Dexamethasone enhances LPS induction of tissue factor expression in human monocytic cells by increasing tissue factor mRNA stability. Journal of Leukocyte Biology 2004;76(1):145-51. Go to original source... Go to PubMed...
    46. Henrikson KP, Greenwood JA, Pentecost BT, Jazin EE, Dickerman HW. Estrogen control of uterine tissue factor messenger ribonucleic acid levels. Endocrinology 1992;130(5):2669-74 Go to original source... Go to PubMed...
    47. Matetzky S, Tani S, Kangavari S, Dimayuga P, Yano J, Xu H, Chyu KY, Fishbein MC, Shah PK, Cercek B. Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation 2000;102(6):602-4. Go to original source... Go to PubMed...
    48. Dardik R, Varon D, Tamarin I, Zivelin A, Salomon O, Shenkman B, Savion N. Homocysteine and oxidized low density lipoprotein enhance platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Journal of Thrombosis and Haemostasis 2000;83(2):338-44. Go to original source... Go to PubMed...
    49. Lockwood CJ, Krikun G, Runic R, Schwartz LB, Mesia AF, Schatz F. Progestin epidermal growth factor regulation of tissue factor expression during decidualization of human endometrial stromal cells. J Clin Endocrinol Metab 2000;85:297-301. Go to original source...
    50. Higgins JR, Walshe JJ, Darling MR, Norris L, Bonnar J. Haemostasis in the uteroplacental and peripheral circulation in normotensive and pre-eclamptic pregnancies. Am J Obstet Gynecol 1998;179:520-6. Go to original source... Go to PubMed...
    51. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Müller M, Risau W, Edgington T, Collen D. Role of tissue factor in embryonic blood vessel development. Nature 1996;383:73-5. Go to original source... Go to PubMed...
    52. Bugge TH, Xiao Q, Kombrinck KW, Flick MJ, Holmback K, Danton MJS, Colbert MC, Witte DP, Fujikawa K, Davie EW, Degen JL. Fatal embryonic bleeding events in mice lacking tissue factor, the cell associated initiator of blood coagulation. Proc Natl Acad Sci USA 1996;93:6258-63. Go to original source... Go to PubMed...
    53. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze Jr GJ. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996;88:1583-7. Go to original source...
    54. Lyall F, Belfort M. Pre-eclampsia. Etiology and clinical practice. Cambridge University Press 2007. P. 3-31,325-335,369.
    55. ©imetka O, Brychtová P, Procházková J, Procházka M. Laboratorní zmìny aktivace endotelu u syndromu HELLP. Gynekolog 2008;2:48-53.
    56. Magee LA. Pre-eclampsia and increased cardivascular risk. Br Med J 2007;335:945-6. Go to original source... Go to PubMed...
    57. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and metaanalysis. Br Med J 2007;335:974-7. Go to original source... Go to PubMed...
    58. He S, Bremme K, Blomback M. Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia. Blood Coagul Fibrinolysis 1997;8:232-8. Go to original source... Go to PubMed...
    59. DG M. Hematologic evidence of disseminated intravascular coagulation in Pre-eclampsia. Obstet Gynecol Surv 1972;399-417. Go to original source...
    60. Howie PW, Prentice CR, McNicol GP. Coagulation, fibrinolysis and platelet function in pre-eclampsia, essential hypertension and placental insufficiency. J ObstetGynaecol Br Commonw 1971;78:992. Go to original source...
    61. Redman CWG, Denson KWE, Beilin LJ, Bolton FG, Stirrat GM. Factor-VIII consumption in pre-eclampsia. Lancet 1977;2:1249-52. Go to original source... Go to PubMed...
    62. Aznar J, Gilabert J, Estelles A, Espana F. Fibrinolytic-activity and protein-c in preeclampsia. Thromb Haemost 1986;55:314-7. Go to original source... Go to PubMed...
    63. Schjetlein R, Abdelnoor M, Haugen G, Husby H, Sandset PM, Wisloff F. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Et Gynecol Scand 1999;78:191-7. Go to original source... Go to PubMed...
    64. Higgins JR, Walshe JJ, Darling MRN, Norris L, Bonnar J. Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. Am J Obstet Gynecol 1998;179:520-6. Go to original source... Go to PubMed...
    65. Dusse LM, Carvalho MG, Getliffe K, Voegeli D, Lwaleed BA, Cooper AJ. Increased circulating thrombomodulin levels in pre-eclampsia. Clin Chim Acta 2008;387:168-71. Go to original source... Go to PubMed...
    66. Vince GS, Starkey PM, Austgulen R, Kwiatkowski D, Redman CWG. Interleukin-6, tumor-necrosis-factor and soluble tumor-necrosis-factor receptors in women with preeclampsia. Br J Obstet Gynaecol 1995;102:20-5. Go to original source... Go to PubMed...
    67. Dusse LM, Rios DRA, Pinheiro MB, Cooper AJ, Lwaleed BA. Pre-eclampsia: Relationship between coagulation, fibrinolysis and inflammation. Clinica Chimica Acta 2011;412:17-21. Go to original source...
    68. Di Paolo S, Volpe P, Grandaliano G. Increased placental expression of tissue factor is associated with abnormal uterine and umbilical Doppler waveforms in severe preeclampsia with fetal growth restriction. J Nephrol 2003;16:650-7. Go to PubMed...
    69. Erez O, Romero R, Hoppensteadt D, Than NG, Fareed J, Mazaki-Tovi S, Espinoza J, Chaiworapongsa T, Kim SS, Yoon BH, Hassan SS, Gotsch F, Friel L, Vaisbuch E, Kusanovic JP. Tissue factor and its natural inhibitor in pre-eclampsia and SGA. J Matern Fetal Neonatal Med 2008;21:855-69. Go to original source... Go to PubMed...
    70. Rousseau A, Favier R, Van Dreden P. Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: new and useful markers for pre-eclampsia? Eur J Obstet Gynecol Reprod Biol 2009;146:46-9. Go to original source... Go to PubMed...
    71. Teng Y, Jiang R, Lin Q, Ding C, Ye Z. The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients. Thromb Res 2010;126:e41-5. Go to original source... Go to PubMed...
    72. Dusse LM, Carvalho MG, Getliffe K, Voegeli D, Cooper AJ, Lwaleed BA. Total plasma tissue factor pathway inhibitor levels in pre-eclampsia. Clin Chim Acta 2008;388:230-2. Go to original source... Go to PubMed...
    73. Lopez-Ramirez Y, Carvajal Z, Arocha-Pinango CL. Hemostatic system parameters of placental extracts in normal pregnancy and severe preeclampsia. Invest Clin 2006;47:233-40. Go to PubMed...
    74. Godoi LC, Gomes KB, Alpoim PN, Carvalho MG, Lwaleed BA, Dusse LMSA. Preeclampsia: the role of tissue factor and tissue factor pathway inhibitor. J Thromb Thrombolysis 2012;34:1-6. Go to original source... Go to PubMed...
    75. Schjetlein R, Abdelnoor M, Haugen G, Husby H, Sandset PM, Wisløff F. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Gynecol Scand 1999;78:191-7. Go to original source... Go to PubMed...
    76. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguere Y. Prevention of Preeclampsia and Intrauterine Growth Restriction With Aspirin Started in Early Pregnancy. Obstetrics & Gynecology 2010;116(2):402-14. Go to original source...

    Return to the content